- Compelling data with STAR0602 demonstrate potent antitumor activity from a single agent in PD-1-refractory solid tumor models
- Clear mechanism of action by expansion of a subset of Vβ T cells with a novel memory phenotype that promotes sustained de novo antitumor immune responses
- STAR0602 is scheduled to begin Phase 1/2 clinical trial (START-001) in Q4 2022
CAMBRIDGE, Mass., October 28, 2022 /PRNewswire/ — Marengo Therapeutics, Inc., a company pioneering novel therapeutics that target the T cell receptor Vβ chain (TCR Vβ) to selectively target the right T cell subsets to fight cancer Activate, today presented the first preclinical proof-of-concept data for STAR0602, its novel TCR agonist antibody, during the 34thth EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA) in Barcelona, Spain. The data presented demonstrated potent anti-tumor activity of STAR0602 in a range of solid tumor models, including those resistant to checkpoint inhibitors such as PD-1/PD-L1.
The oral presentation in the plenum was given by James GuleyMD, Ph.D., Co-Director of the Center for Immuno-Oncology (CIO), Associate Director of the Center for Cancer Research (CCR) at the National Cancer Institute (NCI), and Acting Clinical Director of the NCI.
“STAR0602 offers an entirely new mechanism of selective T-cell activation that increases both the quantity and quality of T-cell responses to the tumor via a mechanism distinct from checkpoint inhibitors,” said Zhen Su, MD, MBA, Chief Executive Officer of Marengo. “These results strongly suggest that our lead product has the potential to become a next-generation IO backbone treatment against a range of solid tumors, representing a novel therapeutic strategy for patients.”
“We are pleased to share the initial data for our STAR0602 program,” he added Andrew Bayliffe, Ph.D., Chief Scientific Officer of Marengo. “These studies demonstrate that our selective Vβ T-cell activators have access to a novel T-cell immunology that has the potential to fundamentally…
